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Background: The aim of this research was to assess the expression of aldehyde dehydrogenase 1 (ALDH1) and epi-
thelial-mesenchymal transition (EMT) markers in head and neck squamous cell carcinoma (HNSCC), and to corre-
late them with the clinical and histopathological parameters of a patient cohort with follow-up over an 8-year period.
Material and Methods: For this, seventeen HNSCC and non-neoplastic adjacent epithelium (AE) samples were 
subjected to laser microdissection and real-time PCR to evaluate the mRNA expression of ALDH1, E-cadherin 
(E-CAD), N-cadherin (N-CAD), and vimentin (VIM). Also, immunohistochemistry was performed for ALDH1, 
E-CAD, N-CAD, and VIM in the tumor center (TC), invasion front (IF), and AE of the seventeen samples. Mann-
Whitney, Kruskal-Wallis and Chi-square tests were used to correlate the mRNA and immunohistochemical ex-
pression with different variables, considering p<0.05. Kaplan-Meier curves were produced for local recurrence, 
regional metastasis and treatment.
Results: A mRNA overexpression of ALDH1 in primary tumors was associated with regional metastasis and a 
high ALDH1 immunostaining was related to metastasis and a worse patient outcome. Additionally, a favorable 
outcome was associated with the transition phase and an unfavorable outcome was associated with EMT event. An 
overall 26.9 months was observed with longer survival associated with surgery and radiotherapy.
Conclusions: However, due to the intense variability inherent to the indicator proteins in the EMT process, the 
complete profile markers related to this biological process should be continuous investigated.
Key words: Aldehyde dehydrogenase 1, epithelial mesenchymal transition, head and neck cancer, squamous cell 
carcinoma, follow-up study.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is 
the sixth most common cancer in the world, correspond-
ing to more than 90% of all tumors (1). Despite various 
studies on carcinogenesis, and attempts to improve the 
patients’ quality of life, the survival rate has remained 
low in the last few decades, at around 50% in five years 
(2,3). This is attributed mainly to regional metastasis, 
recurrences, and the appearance of new primary tumors 
(4). Moreover, evidence suggests that a small population 
of cells, called cancer stem cells (CSCs), play an impor-
tant role in HNSCC recurrence and metastases (5).
During metastasis, stationary tumor epithelial cells be-
come migratory and invasive. A key event involved in 
this process is the epithelial-mesenchymal transition 
(EMT) (6). Once epithelial cells have invaded adjacent 
tissues, they return to their epithelial phenotype, un-
dergoing an inverse process known as mesenchymal-
epithelial transition (MET) (7,8). The EMT and MET 
processes are dynamic events that can define latent or 
active intermediate states of tumor, allowing numerous 
cycles of invasion and metastasis to occur (9).
The aldehyde dehydrogenase 1 (ALDH1) enzyme sub-
family consists of three independent members (1A1, 
1A2 and 1A3) exhibiting different functions and regu-
latory effects in different physiological and pathophysi-
ological conditions, including cancer (10). Moreover, 
ALDH1 has been used as a CSCs marker, and its ex-
pression is associated with tumors with greater inva-
siveness, metastases, treatment resistance, and worse 
prognosis in HNSCC (10).
The expression of ALDH1 in HNSCC has been previ-
ously studied in the tumor center (TC), invasion front 
(IF), and adjacent non-neoplastic epithelium (AE), 
showing ALDH1 is useful in identifying tumors with 
aggressive behavior (11). Moreover, ALDH1 expres-
sion was previously correlated EMT phenotypes and 
considered an epithelial-like marker, nevertheless the 
exclusively ALDH1 role in the HNSCC cancer correlat-
ing with EMT was not previously investigated (12-14). 
Thus, a better understanding of the other processes in-
volved in carcinogenesis and tumor progression is cru-
cial to understanding the mechanisms used by cells to 
disseminate and invade (7,15,16).
The aim of this study was to evaluate the mRNA ex-
pression of ALDH1, E-cadherin (E-CAD), N-cadherin 
(N-CAD), and vimentin (VIM) in HNSCC and AE, and 
their immunoexpression in the TC, IF, and AE. Further, 
we aimed to correlate the obtained results with clinical 
parameters, histopathological characteristics, and pa-
tients’ outcomes after an 8-year follow-up period.
Material and Methods
- Sample description
To perform this study, samples were obtained from 
specimens during surgical treatment attempts. The 
samples consisted of 17 paraffin blocks and 34 fresh tis-
sues (17 TC and 17 AE) from the same patients with pri-
mary HNSCC in the oral cavity (10 cases), oropharyinx 
(1 case) and hypopharynx (2 cases vocal cords, 2 cases 
larynx, 1 case subglottis and 1 case piriform sinus), who 
did not receive any prior treatment. All patients under-
went surgical treatment exclusively.
- Clinical and histopathological characteristics of tu-
mors
Data regarding tumor location and clinical stage were 
obtained from hospital records. Histopathological grad-
ing was performed by two previously trained patholo-
gists, in accordance with Bryne’s criteria (17).
The patients included in this study were divided into 
two groups in accordance with the follow-up 8 years 
on: favorable outcome (alive and without recurrence of 
the tumor), and unfavorable outcome (death by tumor 
recurrence or metastasis). This time was considered 
due to the maximum period of follow-up reached to the 
study.
- Laser microdissection
A cryostat was used to prepare 22 μm thick sections 
of each sample. The sections were transferred to a pre-
sterilized PALM® MembraneSlide (Zeiss®, DEU), 
briefly heated, and allowed to dry at −20 °C for 2–3 
minutes. The slide was then incubated in 70% etha-
nol for two minutes. Subsequently, staining was car-
ried out in 1% cresyl violet (Sigma-Aldrich®, USA) for 
30 seconds, followed by washing with 70% and 100% 
ethanol. The slides were kept immersed in 100% etha-
nol until sectioning was carried out, and then dried at 
room temperature for 1–2 minutes. The microdissection 
technique was performed with the PALM Microbeam 
IPZ laser microdissector (Zeiss®, DEU) following the 
manufacturer's instructions.
- Analysis of mRNA expression
RNA extraction from 34 fresh tissues samples (17 TC 
and 17 AE) followed the RNA concentration was evalu-
ated by spectrophotometric reading at 260 and 280nm 
wavelengths. The estimation of the degree of purity was 
through the A260/A280 ratio and 4 µL with 2µg (0.5 
µg/µL) of total mRNA per sample were used to syn-
thesis of cDNA from previously microdissected areas 
using the RNeasy Micro kit (Qiagen®, USA) and the 
SuperScript® VILO™ cDNA Synthesis Kit (Invitro-
gen®, USA), respectively, following the manufacturers’ 
instructions. The cDNA samples obtained were then 
subjected to real-time PCR to analyze the mRNA ex-
pression of markers of the EMT process and ALDH1.
TaqMan® primers for E-CAD (Hs01023894_m1), N-
CAD (Hs00983056_m1), VIM (Hs00185584_m1), and 
ALDH1 (Hs00946916_m1) from Life Technologies®, 
USA, were used for the mRNA expression analysis. All 
reactions were performed in triplicate and normalized to 
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GAPDH (Hs99999905_m1) and β-actin (Hs99999903_
m1) (Life Technologies®, USA). A previously tested 
sample was used as a positive control, while ultrapure 
water was used as the negative control including real-
time PCR reagents with no mRNA material. All reac-
tions were performed in a Step One Plus® thermocycler 
(Life Technologies®, USA).
- Immunohistochemical quantification and reproduc-
ibility
The immunohistochemical staining for each marker was 
evaluated in the different areas of interest by two previ-
ously trained examiners using light microscopy with a 
final amplification of 400X. Cells with brown staining, 
irrespective of the intensity of the marking, were con-
sidered positive for E-CAD (membrane; Cell Signaling; 
Clone 24E10; 1:200), N-CAD (cytoplasm and nucleus; 
Abcam; Clone AB18203; 1:300), and VIM (membrane; 
Dako; Clone V9; 1:100). The score was 1 (0–50 % of im-
munopositive cells) or 2 (51–100% of immunopositive 
cells) (11). As for ALDH1 (cytoplasm; DB Biosciences; 
Clone 44; 1:50), the score was 1 (<5% of immunoposi-
tive cells) or 2 (≥5% of immunopositive cells) (11).
Reproducibility was confirmed during the course of the 
study. For every 10 slides evaluated, one was randomly 
selected for re-evaluation after a period of 7 days (Kap-
pa > 0.7).
- Analysis of the EMT process in tumor samples and 
classification of AE
The tumor samples were classified as low E-CAD ex-
pression and high N-CAD and/or VIM expression, 
high E-CAD expression and low N-CAD and/or VIM 
expression, or transition phase (tumors that did not fit 
the score criteria). For the AE, a qualitative definition 
was used: normal (high E-CAD expression, and low 
N-CAD and VIM expression) or altered (when the im-
munostaining revealed distinct patterns) (6,18). The im-
munohistochemical scores were considered to classifi-
cation tumors low E-CAD expression and high N-CAD 
(E-CAD – Score 1/N-CAD-Score 2), high E-CAD ex-
pression and low N-CAD (E-CAD – Score 2/N-CAD-
Score 1), transition (E-CAD – Score 1/N-CAD-Score 1 
or ECAD-Score 2 NCAD-Score 2).
- Statistical analysis
A Chi-square test was used to verify the association 
between the immunohistochemical expression and the 
other variables. The mRNA expression analysis and its 
relationship to the study variables were compared us-
ing the Mann-Whitney or Kruskal-Wallis test using the 
SPSS software, version 21 (IBM Corporation, USA) 
(significance level set at p<0.05). Life tables were used 
to calculate survival rates at 6, 18, 24, 36, and 48 months 
after diagnosis with a complete follow-up of 8 years. 
Kaplan-Meier curves were produced for local recur-
rence, regional metastasis and treatment with a confi-
dence interval of 95%.
Results
The clinical and histopathological parameters of the 
samples are summarized in Table 1. The mean age in 
the favorable outcome group was 53.3 years (range 39–
70), and that in the unfavorable outcome group was 60.2 
years (range 48–72). The majority of individuals in both 
groups were male (85.7% and 100%) and Caucasian 
(57.1% and 90%). Regarding alcohol consumption and 
tobacco use, the majority in the favorable outcome group 
were alcohol drinkers and smokers (57.1%), while in the 
unfavorable outcome group most were former drinkers 
(60%) and former smokers (80%). Furthermore, the ma-
jority of individuals in the favorable outcome group had 
tumors of sizes T1 and T2 (85.7%), with an absence of 
regional metastasis (71.4%) and located in the oral cav-
ity (57.1%). In the unfavorable outcome group, there was 
a prevalence of tumors of a larger size (T3 and T4), with 
the presence of regional metastases, and located in the 
oral cavity, all with a rate of 60% (Table 1).
Variables Favorable Unfavorable  p Valuen=7  (%) n=10 (%)
Gender
Female 1 (14.3) 0 (0.00)
0.412Male 6 (85.7) 10 (100)
Ethnic origin
Caucasian 4 (57.1) 9 (90.0)
0.250Not caucasian 3 (42.9) 1 (10.0)
Tobacco
Smoker 4 (57.1) 2 (20.0)
0.162Former smoker 3 (42.9) 8 (80.0)
Alcohol
Rarely drink 2 (28.6) 1 (10.0)
0.234Drinker 4 (57.1) 3 (30.0)
Former drinker 1 (14.3) 6 (60.0)
Tumor size 
T1 and T2 6 (85.7) 4 (40.0)
0.134T3 and T4 1 (14.3) 6 (60.0)
Regional metastasis
N0 2 (28.6) 6 (60.0)
0.335N1, N2 and N3 5 (71.4) 4 (40.0)
Histopathological grading
Grade I 0 (0.0) 2 (20.0)
0.606Grade II 2 (28.6) 2 (20.0)
Grade III 5 (71.4) 6 (60.0)
Tumor localization
Oral cavity 4 (57.1) 6 (60.0)
>0.999Neck region* 3 (42.9) 4 (40.0)
Fisher’s exact test. Significance level of p <0.05. Favorable outcome: 
alive and without recurrence of the tumor; Unfavorable outcome: 
death by tumor recurrence or metastasis *one oropharyinx, hypo-
pharynx (two vocal cords, two larynx, one subglottis and one piri-
form sinus).
Table 1: Sample description according to patients’ outcome with 
follow-up of 8 years.
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- Survival by local recurrence 
The mean overall duration of survival was 26.9 months 
(range: 6 to 48 months), and the survival rates at 6, 18, 
24, 36 and 48 were: 0.9, 0.8, 0.6, 0.2 and 0, respectively. 
The mean survival time was longer for no recurrence 
(36.6 months, 95% CI: 25.2 to 42.1) followed by with re-
currence (22.9 months, 95% CI: 18.6 to 27.3) (Fig. 1), but 
this was not significant (chi square (1) = 3.726, p=0.054).
- Survival by regional metastasis
The mean overall duration of survival was 26.9 months 
(range: 6 to 48 months), and the survival rates at 6, 18, 
24, 36 and 48 were: 0.8, 0.6, 0.4, 0.2 and 0, respectively. 
The mean survival time was longer for N0 (31.7 months, 
95% CI: 24.2 to 39.2) followed by N1, N2 and N3 (23.3 
months, 95% CI: 17.3 to 29.3) (Fig. 1), but this was not 
significant (chi square [1] = 2.733, p=0.09).
- Survival by treatment
The mean overall duration of survival was 26.9 months 
(range: 6 to 48 months), and the survival rates at 6, 18, 
24, 36 and 48 were: 0.9, 0.67, 0.36, 0.25 and 0, respec-
tively. The mean survival time was longer for surgery 
and radiotherapy (33 months, 95% CI: 24.7 to 41.3) fol-
lowed by surgery, radiotherapy and chemotherapy (24 
months, 95% CI: 24 to 24) and surgery (23.5 months, 
95% CI: 17.8 to 29.33) (Fig. 1), but this was not signifi-
cant (chi square [2] = 3.148, p= 0.207).
- mRNA expression 
ALDH1 mRNA overexpression in the tumor samples 
was associated with the presence of regional metastasis 
(p=0.021). E-CAD overexpression in the tumor was as-
sociated with a favorable evolution (p=0.051) (Table 2).
N-CAD was overexpressed in the AE when compared 
to the tumor (p=0.045). E-CAD and ALDH1 expression 
were not significant p=0.323 and (p=0.101). Conversely, 
VIM was overexpressed in the tumors when compared 
to the AE (p=0.001) (Fig. 2).
Fig. 1: Survival curves. A. Survival by local recurrence. A longer survival rates of HNSCC patients with no recurrence was reached 
(No:36.6 months/Yes:22.9 months). B. Survival by regional metastasis. Note a longer survival rates of HNSCC patients with absence 
of regional metastasis was observed (N0: 31.7 months/N1, N2 and N3: 23.3 months). C. Survival by treatment. Note, the HNSCC 
patients treated with surgery and radiotherapy presented longer survival rates (33 months) comparative with surgery, radiotherapy 
and chemotherapy (24 months) and exclusively surgery (23.5 months).
Fig. 2: Relative mRNA expression in the tumor and adjacent epithelium (AE) of head and neck squamous cell carcinoma (HNSCC) 
samples. N-CAD was overexpressed in the AE (p=0.045). E-CAD expression was not significant p=0.323. ALDH1 expression was 
not significant (p=0.101). VIM was overexpressed in the tumors (p=0.001).
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Variables
ALDH1 E-CADHERIN N-CADHERIN VIMENTIN
 Median (25-75) Median (25-75) Median (25-75)  Median (25-75)
 TUMOR AE TUMOR AE TUMOR AE TUMOR AE
Follow Up (8 years)
Favorable
0.04 2,46 3,8 1,36 0.00 0.04 7.65 0.57 
 (0.02-7.29)  (0.39-13.25) (2.82-12.27) (1.16-3.93)  (0.00-0.02) (0.02-0.61)  (3.41-3.51) (0.33-2.16)
Unfavorable
0.23 4.05 2,15 2.79 0.02 0.02 3.37 1.23
 (0.08-3.36)  (0.20-8.26) (1.62-4,74) (1.35-4.23)  (0.01-0.02)  (0.01-0.10) (2.40-11.19)  (0.37-4.93)
P 0.299 0.874 0.051 0.315 0.107 0.396 0.558 0.097
Tumor size
T1 and T2
0.05 2.77 2.97 2.60 0.01 0.03 7.15 1.03
 (0.03-3.36)  (0.47-10.25)  (1.91-8.56) (1.78-3.42) (0.00-0,03)  (0.01-0.34) (2.89-9.96)  (0.42-2.83)
T3 and T4
0.23 0.86 3.70 2.36 0,01 0.02 3.81 0.98 
(0.01-3.78)  (0.07-9.27)  (1.74-4.30) (1.31-4.45)  (0.00-0,03)  (0.01-0.08) (2.32-10.87) (0.97-2.52)
P 0.230 0.5848 0.6430 0.8217 0.7984 0.6010 0.6430 0.8011
Regional metastasis
N0
0.05 2.46 3.13 2.60 0.03 3 7.65 0.99 
(0.03-2.52)  (0.47-5.65) (2.35-9.16) (1.78-5.00) (0.00-0.03) (0.01-0.34) (2.84-10.19) (0.39-2.92)
N1, N2 and N3
1.89 5.05 3.07 0.36 0.01 0.02 5.23 1.02
 (0.12-7.99) (0.07-15.77) (1.44-5.65) (1.30-4.01) (0.01-0.02) (0.01-0.08) (2.35-10.88)  (0.97-2.26)
P 0.021* 0.711 0.501 0.874 0.661 0.465 0.773 0.773
Tumor graduation
Grade I
1.74 2.21 3.42 2.03 0.01 0.03 3.70 1.59
(0.12- -)  (0.37- -) (0.81- -)    (1.69- -) (0.01-0.01)  (0.03-0.03) (0.61- -)  (0.66- -)
Grade II
0.06 0.71 3.26 2.43 0.03 0.03 6.46 1.87
(0.02- -)  (0.43-5.65) (2.19-10.13) (1.36-8.13) (0.03- -)  (0.00- -) (3.05-10.53)  (0.26-3.60)
Grade III
 
0.16 3.91 3.13 2.69 0.01 0.03 6.65 0.98
 (0.04-4.83)  (0.05-13.88) (1.74-6.10) (1.73-4.12)  (0.00-0.02)  (0.01-0.28) (2.42-11.31)  (0.57-2.16)
P 0.663a 0.744a 0.816a 0.729a 0.206a 0.875a 0.563a 0.846a
Kruskal-Wallis test.* Statistically significant relationship a U Mann-Whitney test. (p<0.05)
- Immunohistochemical findings
During the immunohistochemical processing, three sam-
ples were excluded, leaving the final sample count of 14 
individuals. ALDH1 overexpression was associated with 
an unfavorable outcome in both the IF (p=0.023) and TC 
(p=0.031). ALDH1 overexpression in the IF was associated 
with the presence of regional metastasis (p=0.031) (Table 3).
E-CAD overexpression in the TC was associated with an 
unfavorable patient outcome (p=0.031) (Table 3). Low 
E-CAD immunoexpression was associated with altered 
epithelia (p=0.027) (data not shown). Fig. 3 illustrates the 
complete immunoexpression findings.
Regarding VIM, a score of 1 was observed in 100% of 
the three areas studied. Because it is a constant variable, 
no statistical analysis was performed (data not shown).
- Low E-CAD and High N-CAD/High E-CAD and low 
N-CAD or transition phases in IF and TC
In the IF, one sample was classified as low E-CAD and 
high N-CAD, ten as transition phase, and three as high 
E-CAD and low N-CAD. A significant association be-
tween a low expression of E-CAD and the low E-CAD 
and high N-CAD/transition phases, as well as between 
a high expression of this protein and high E-CAD and 
low N-CAD (p=0.011), was seen. Additionally, an asso-
ciation was also observed between the classified histo-
pathological grading and low E-CAD and high N-CAD, 
as well as between the moderate and transition phases, 
and between the poor outcome and high E-CAD and low 
N-CAD (p=0.003) (Table 4).
In the TC, one sample was classified as low E-CAD and 
high N-CAD, eight as transition phase, and five as high 
E-CAD and low N-CAD. An association was found be-
tween a favorable outcome and the transition phase, as 
well as between an unfavorable outcome and low E-
CAD and high N-CAD/ high E-CAD and low N-CAD 
(p=0.048). Another significant association was found in 
relation to E-CAD expression, in which low expression 
was associated with low E-CAD and high N-CAD /tran-
sition phase, and overexpression with high E-CAD and 
low N-CAD (p=0.003) (Table 4).
Table 2: Relationship among patients follow-up, tumor size, regional metastasis, tumor gradation and mRNA.
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 ALDH1 E-CADHERIN N-CADHERIN
n (%) n (%) n (%) n (%) n (%) n (%)
INVASION FRONT
Group/follow up  
1- Favorable 4 (80.0) 1 (11.1) 4 (40.0)  1 (25.0) 5 (41.7) 0 (0.00)
2- Unfavorable 1 (20.0)  8 (88.9) 6 (60.0)  3 (75.0) 7 (58.3) 2 (100)
p=0.023* p<0.999 p=0.505
Tumor Size         
T1 and T2 4 (80.0) 4 (44.4) 5 (50.0) 1 (25.0) 7 (58.3) 1 (50.0)
T3 and T4 1 (20.0) 5 (55.6) 5 (50.0)  3 (75.0) 5 (41.7) 1 (50.0)
p=0.301 p=0.580 p<0.999
Regional Metastasis
N0 5 (100) 3 (33.3) 5 (50.0) 3 (75.0) 8 (66.7) 0 (0.00)
N1, N2 and N3 0 (0.00)  6 (66.7) 5 (50.0)    1 (25.0) 4 (33.3)        2 (100)
p=0.031* p=0.580 p=0.165
Graduation
Grade I 0 (0.00) 2 (22.2) 2 (20.0) 0 (0.00) 1 (08.3)  1 (50.0)
Grade II 3 (60.0) 1 (11.1) 1 (10.0) 3 (75.0) 4 (33.3)  0 (0.00)




1- Favorable 5 (62.5) 0 (0.00) 5 (62.5) 0 (0.00)   5 (41.7)    0 (0.00)
2- Unfavorable 3 (37.5) 6 (100)    3 (37.5)    6 (100) 7 (58.3)    2 (100)
p= 0.031* p=0.031* p=0.505
Tumor Size
T1 e T2 4 (50.0) 4 (66.7) 4 (50.0) 4 (66.7) 7 (58.3) 1 (50.0)
T3 e T4 4 (50.0) 2 (33.3) 4 (50.0) 2 (33.3) 5 (41.7) 1 (50.0)
p=0.627 p=0.627 p<0.999
Regional Metastasis
N0 5 (62.5) 3 (50.0) 4 (50.0) 4 (66.7) 8 (66.7)   0 (0.00)
N1, N2 and N3 3 (37.5)  3 (50.0) 4 (50.0)    2 (33.3) 4 (33.3)  2 (100)
p<0.999 p=0.627 p=0.165
Graduation
Grade I     1 (12.5) 1 (16.7) 1 (12.5) 1 (16.7) 1 (08.3)  1 (50.0)
Grade II     3 (37.5) 1 (16.7) 2 (25.0) 2 (33.3) 4 (33.3)  0 (0.00)
Grade III     4 (50.0) 4 (66.7) 5 (62.5) 3 (50.0) 7 (58.3)  1 (50.0)
p=0.770 p<0.999  p=0.341
Fisher’s exact test. * Statistically significant association (p<0.05)
Table 3: Association among ALDH1, E-CAD, N-CAD immunoexpression in tumor areas and clinical parameters.
Low E-CAD  
High N-CAD TRANSITION
High E-CAD 
Low N-CAD p VALUE
INVASION FRONT n=1 (%) n=10 (%) n=3 (%)
Graduation
Grade I 1 (100) 1 (10.0) 0 (0.00)
0.003*Grade II 0 (0.00) 1 (10.0) 3 (100)
Grade III 0 (0.00) 8 (80.0) 0 (0.00)
E-CAD expression
Score 1 1 (100) 9 (90.0) 0 (0.00) 0.011*
Score 2 0 (0.00) 1 (10.0) 3 (100)
TUMOR CENTER n=1 (%) n=8 (%) n=5 (%)
Follow up
Favorable 0 (0.00) 5 (62.5) 0 (0.00) 0.048*
Unfavorable 1 (100) 3 (37.5) 5 (100)
E-CAD expression
Score 1 1 (100) 7 (87.5) 0 (0.00) 0.003*
Score 2 0 (0.00) 1 (12.5) 5 (100)
Fisher’s exact test. * Statistically significant result (significance level of p <0.05)
Table 4: Association between EMT process (low E-CAD and high N-CAD/transition/high E-CAD and low N-CAD) in tumor 
areas and studied variables.
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Fig. 3: Immunostaining profile of E-CAD, N-CAD, and ALDH1 in the adjacent epithelium (AE), tumor center (TC), and 
invasive front (IF) of head and neck squamous cell carcinoma (HNSCC) samples. Note the tumor patterns classified as 
epithelial-mesenchymal transition (EMT) (low E-cadherin, high N-cadherin) (B, C, K, and L) and mesenchymal-epithelial 
transition (MET) (high E-cadherin, low N-cadherin) (E, F, H, and I). ALDH1 presents evident positivity in the TC and IF 
of HNSCC samples.
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Discussion
To our knowledge, this is the first study on solid tumors 
to have evaluated the expression of ALDH1 and mol-
ecules involved in the EMT process in different areas 
of HNSCC and AE, by isolating the epithelial tissue 
from the connective tissue. In addition, a descriptive 
analysis of the results of mRNA expression with the 
immunostaining of the studied proteins was conducted 
in the present study. However, there was no access to 
matching samples of lymph node metastasis from their 
cohort in order to evaluate the expression of ALDH1 
and EMT markers. Also, a convenience sample includ-
ing different anatomic sites was used which presents as 
a weakness of study.
The demographic profile of the participating individu-
als, and the clinical characteristics of the tumors, were 
similar to those of different consulted studies (19,20). In 
addition, a large part of the patients had been exposed 
to habits considered risk factors for the development of 
HNSCC (21). A complete recorded prospectively data 
as from 2009 until 2017 was conducted, and all patients’ 
data were round renewed until the last follow-up date 
accessed by researchers. Our overall survival was simi-
lar to the literature, and this may be reflection of clinical 
status and treatment. Also, a survival analysis by recur-
rence, regional metastasis and treatment was included. 
The overall 26.9 months survival was observed consid-
ering local recurrence, regional metastasis and therapy 
treatment established. Surgery and radiotherapy pre-
sented better results (33 months) followed by surgery, 
radiotherapy and chemotherapy (24 months) and sur-
gery (23.5 months). Moreover, patients with local recur-
rence (No:36.6/Yes:22.9) and regional metastasis (N0: 
31.7/N1, N2 and N3: 23.3) presented shorter survival. 
Our survival parameters are comparable than previous 
literature and reinforce the role of adjuvant therapies 
such as radiotherapy with an increase of survival rates 
when comparable exclusively surgery (3,4).
In our study, ALDH1 mRNA overexpression and im-
munoexpression were associated to the presence of 
regional metastases. The presence of ALDH1 in can-
cer cells with a greater invasive capacity has already 
been described (11,22,23). Likewise, previous studies 
have reported the association between EMT and CSCs 
markers and ALDH1 expression in primary tumors and 
regional metastasis (12,13,24-26). This suggests that 
ALDH1 positivity can be associated to cells in the EMT 
process and, consequently, to metastasis (24,26). Fur-
thermore, high ALDH1 immunoexpression, regardless 
of the assessed tumor area, was associated with an unfa-
vorable outcome, suggesting this marker could be used 
as an indicator of worst prognosis for patients with HN-
SCC (24,27). Moreover, high ALDH1 expression was 
recently associated with a high intensity of tumor bud-
ding. This reinforces the role of CSCs in carcinogenesis 
through ALDH1 expression, which can accelerate the 
invasion of cancer cells and, consequently, worsen the 
biological tumor behavior (28).
Regarding E-CAD in the AE, we observed low mRNA 
expression and the preservation of immunostaining, 
suggesting that the non-neoplastic epithelial tissue ex-
presses adequate levels of E-CAD protein in regions of 
cell adhesion, without necessarily entailing oscillation 
in mRNA expression. The opposite situation was found 
in the tumor, where there was a high level of mRNA 
expression and low protein immunostaining, suggest-
ing that a higher production of mRNA does not neces-
sarily translate into protein synthesis by the neoplastic 
cells. Similar results were observed in the N-CAD gene 
and in immunostaining in the AE and VIM in the tu-
mor, wherein an intense production of mRNA does not 
necessarily determine high protein synthesis. However, 
the low expression of E-CAD and the overexpression 
of N-CAD in the AE can suggest that the initial gene 
deregulation observed through mRNA expression with 
no evident modification in protein synthesis is crucial to 
the loss of adhesion of the epithelium. Thus, these find-
ings suggest the suspicious of field cancerization with 
no morphological modification.
Analyzing the results of the relationship between the 
adhesion molecule immunoexpression and the clinical 
parameters, we observed an association between high 
E-CAD immunoexpression in the TC and an unfavor-
able outcome in patients, a result similar to that found 
in breast tumors (29). However, N-CAD and VIM im-
munoexpression did not show the same relationship re-
gardless of the evaluated region, which suggests these 
markers are not relevant to prognostic evaluation in the 
studied sample.
The EMT process in tumors is a dynamic and com-
plex biological process, leading to the need to evaluate 
its intermediary stages individually (19). In the pres-
ent study, we evaluated the association between cases 
classified as low E-CAD and high N-CAD, transition, 
high E-CAD and low N-CAD, and different variables. 
A significant association was observed between low E-
CAD immunoexpression in tumors and EMT/transition 
phases, corroborating published findings according to 
which cells do not need to gain mesenchymal features 
in the initial EMT process (18). Therefore, more impor-
tant than the gain of mesenchymal properties is the loss 
of E-CAD expression that directs the malignant cell to 
initiate the EMT process.
In the IF, the transition phase was related to undifferen-
tiated tumors, supporting the results of previous studies 
that associated an intermediate EMT state with undif-
ferentiated cells or cells exhibiting CSCs properties 
(18,25). In addition, the existence of CSCs at the IF was 
previously reported (30). Moreover, it may be difficult 
to interpret the results of the transition phase due to its 
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plasticity, whereby a migratory cell can express both 
epithelial and mesenchymal properties.
Evaluating the EMT process in the TC, we observed an 
association between the low E-CAD and high N-CAD/ 
high E-CAD and low N-CAD phases and an unfavor-
able patient outcome, while the transition phase was 
related to a favorable outcome. This distinct behavior 
can be explained by the fact that each cancer type has 
a distinct propensity to exhibit diverse EMT states (18). 
Nieto et al. [2016] reported that these different EMT 
states may explain the inconclusive clinical significance 
of EMT. The authors suggest the EMT process is a focal 
event, occurring in relation to the local microenviron-
ment of the tumor cells (18,26). Besides, there is a cellu-
lar hierarchy within a tumor population, with neoplastic 
cells in distinct stages of proliferation and differentia-
tion, which can affect the assessment of the EMT pro-
cess through immunostaining (18). Thus, the influence 
of the EMT process on cancer progression and patient 
survival is not completely understood.
According to the obtained results, it can be concluded 
that ALDH1 overexpression is associated to regional 
metastasis and a worse outcome in HNSCC patients 
based on clinical and microscopical parameters. How-
ever, the same conclusion should be carefully drawn 
when considering EMT mechanisms, due to the high 
variability inherent in the process, suggesting the need 
for further studies to investigate the prognostic value of 
these mechanisms.
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